Get ready to energize your life?
Top Offers Only Today
Support your health and step-up your mental focus
post in: Health Date:22 Nov 2017, 13:59 views:4306
Warnings, included as part of the, precautions section.
Asthma-Related Death, long-acting beta2-adrenergic agonists, such as formoterol, the active ingredient in foradil aerolizer, increase the risk of asthma-related death.
Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from laba.
Because of this risk, use of foradil aerolizer for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g. Discontinue foradil aerolizer) if possible boot without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid.
Do not use foradil aerolizer for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids.
Pediatric and Adolescent Patients, available data from controlled clinical trials suggest that laba increase the risk of asthma-related hospitalization in pediatric and adolescent patients. For pediatric and adolescent patients with asthma who require addition of a laba to an inhaled corticosteroid, a fixed-dose combination product containing both an inhaled corticosteroid and laba should ordinarily be considered to ensure adherence with both drugs.
In cases where use of a separate long-term asthma control medication (e.g. Inhaled corticosteroid) and laba is clinically indicated, appropriate steps must be taken to ensure adherence with both treatment components.
If adherence cannot bitter be assured, a fixed-dose combination product containing both an inhaled corticosteroid and laba is recommended. A 28-week, placebo-controlled US study comparing the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving receptors salmeterol (13/13,176 in patients treated with salmeterol. 3/13,179 in patients treated with placebo;.37, 95.25,.34).
The increased risk of asthma-related death is considered a class effect of the long-acting beta2-adrenergic agonists, including formoterol.